Crossmark

Clinical exome sequencing in France and Quebec: what are the challenges? What does the future hold?

Crossref DOI link: https://doi.org/10.1186/s40504-018-0081-2

Published Online: 2018-08-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bertier, Gabrielle https://orcid.org/0000-0002-3319-3721
Joly, Yann
Funding

Funding for this research was provided by:

Université Toulouse III - Paul Sabatier (Axes stratégiques 2014)

Canadian Institutes of Health Research (EXACTIS)

Fonds de Recherche du Québec - Santé (30719)

Centre de Développement des Composites du Québec (CA)

Mitacs (Globalinks Research Award IT06972)

Network of Applied Genetic Medicine (Fellowship in Applied Genetics 2015)
License Information

Text and Data Mining valid from 2018-08-01
More Information

Article History

Received: 13 April 2018

Accepted: 2 July 2018

First Online: 1 August 2018

Ethics approval and consent to participate

: The procedures followed were assessed by the responsible review committees. This work was approved by the McGill Faculty of Medicine Institutional Review Board (Study number A12-M66-15A), and by Inserm’s Institutional Review Board (approval number 15–253). According to the recommendations of these committees, oral consent was obtained from participants in France, and written consent for participants in Quebec.

: Not applicable.

: The authors declare that they have no competing interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.